Chronic lung disease of infancy or bronchopulmonary dysplasia Respiratory Chronic lung disease
Conditions
Interventions
Children will receive inhaled corticosteroids or placebo for 6 weeks, pulmonary function either forced expiratory volume in 1 second (FEV1) or impulse oscillometry and quality of life will be assessed
Sponsors
University of Calgary (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 3 - 7 year old children with history of chronic lung disease of infancy 2. Premature birth at 36 weeks gestation or less 3. Clinical and radiological diagnosis of CLD. Patient charts will be reviewed and the x-rays will be reviewed, even if there is no x-ray findings patients will be included if they fulfil the other criteria. 4. Requirement of supplemental oxygen to maintain saturation of 90%, for at least 36 weeks corrected gestation
Exclusion criteria
Exclusion criteria: 1. Cardiovascular disease other than patent ductus arteriosus (PDA) 2. Those with severe neurological disease or developmental delay 3. Oxygen requirement for respiratory diagnosis other than CLD, e.g., congenital diaphragmatic hernia and aspiration 4. An inability to perform spirometry or impulse oscillometry (IOS) 5. Noncompliance with therapy 6. Pneumonia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in respiratory system resistance at 5 Hz frequency using impulse oscillometry after 6 weeks of inhaled corticosteroids in CLD. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in quality of life system score using Child Health Questionnaire (CHQ) and FEV1 response to bronchodilators (Salbutamol) after inhaled corticosteroids treatment for 6 weeks in CLD. | — |
Countries
Canada
Outcome results
None listed